Sanofi's Insulin Aspart Biosimilar Receives CHMP's Positive Recommendation for Approval in the EU
Shots:
- The CHMP’s positive recommendation is based on the clinical development program that comprises P-I PK/PD study that evaluates product’s similarity in exposure and activity1 and P-III Gemelli 12 study to evaluate the safety & efficacy
- The clinical program involves 600+ patients with T1D or T2D. Both the studies compared the biosimilar to insulin aspart 100 Units/mL as currently approved for use by adults with T1D/ T2D in the US and EU
- The CHMP’s positive opinion marks the first regulatory milestone in the EU for any biosimilar insulin aspart product. Additionally- Sanofi has two rapid-acting insulin analogs approved in the EU
Click here to read full press release/ article | Ref: EMA | Image: Behnace
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com